Floatz logo

Daunorubicin

Acute Myeloid Leukemia With FLT3/ITD Mutation

Gruppo Italiano Malattie EMatologiche dell'AdultoPhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
89/ 100

Competitive context

11 Active assets in the Acute Myeloid Leukemia With FLT3/ITD Mutation cohort.

Asset / SponsorPhaseRating
Gilteritinib
The First Affiliated Hospital of Soochow University
Phase 3BB
Azacitidine
French Innovative Leukemia Organisation
Phase 2BB
Cytosin-Arabinosid
First Affiliated Hospital of Zhejiang University
Phase 3BB
Sorafenib
The First Affiliated Hospital of Soochow University
Phase 3BB
xy0206
Shijiazhuang Yiling Pharmaceutical Co. Ltd
Phase 3BB

View all 23 →

Same molecule, other indications

Daunorubicin is also rated in:

acute myeloid leukemia by FAB classificationDormant
BBB
Indicative ·
78 / 100
View asset →
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
77 / 100
View asset →
acute monocytic leukemiaDormant
BBB
Indicative ·
77 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →